Long-term follow-up for cell therapy participants
Part of Cancer clinical trials.
This study checks how people do over time after receiving an “adoptive cell therapy” treatment. It helps researchers understand long-term safety and outcomes after prior participation in related studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received at least one dose of an ADP adoptive cell therapy treatment
- You previously finished a related ADP-sponsored or supported treatment study, or you withdrew from it
- If you joined through “managed access” with a GSK cell therapy, you must have completed that treatment too
- You can follow the study’s contraception rules while you’re in the study
- You’re able to understand and sign the informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a long-term check-in for people who previously received gene-modified T-cell infusions in a related Celgene/Juno/BMS trial. It helps researchers track safety and long-term effects over time.
This study checks how people do long-term after stem cell transplant, cellular therapy, or gene therapy. It may help doctors track longer-term health effects and recovery and improve future care.
This study is a long-term follow-up for people who have already received a cell or gene therapy in a previous AstraZeneca trial. It helps researchers monitor your health over time to make sure the therapy is safe and effective.
This study follows people long-term after receiving a specific gene-cell treatment called AGT103-T. It helps researchers check long-term safety and outcomes, which can guide future care for others.
This study is for people who have already received a special kind of cell therapy that involved modifying their genes. The purpose is to keep track of their health over a longer period of time to see how they are doing after the treatment.
This study is for people who have already received a specific type of cell therapy (CAR T-cell therapy) made by Galapagos. It will follow them over the long term to see how they are doing.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.